BlackRock Health Sciences Term Trust (BMEZ)

The investment case here is defined by a stark divergence between a generous current yield and a deteriorating business trajectory. While the 8.1% dividend yield is attractive on the surface, it masks a significant capital erosion problem: the trust has lost over 40% of its value over the last five years, and the most recent annual return was negative. This multi-year decline suggests the market views the underlying health sciences portfolio as fundamentally impaired, likely due to interest rate sensitivity or sector rotation pressures, rather than seeing it as a value opportunity. The recent price action shows the stock hovering near its 52-week lows with minimal momentum, confirming a lack of near-term catalysts to reverse the downtrend. Regarding the income, while the payout ratio of roughly 44% indicates the dividend is currently covered by earnings, the history reveals a dangerous pattern of dividend cuts—dropping from roughly $0.18 per share in early 2025 to $0.11 in late 2026. This cut signals that the high yield was unsustainable and that future distributions face significant risk of further reduction if the asset base continues to shrink.